HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
TRAF5
TNF receptor associated factor 5
Chromosome 1 · 1q32.3
NCBI Gene: 7188Ensembl: ENSG00000082512.16HGNC: HGNC:12035UniProt: O00463
148PubMed Papers
20Diseases
0Drugs
1Pathogenic Variants
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
ubiquitin protein ligase bindingtumor necrosis factor-mediated signaling pathwayprotein bindingCD40 signaling pathwaymultiple myelomamathematical abilityhepatocellular carcinomaposterior cortical atrophy
✦AI Summary

TRAF5 (TNF receptor associated factor 5) is an adapter protein that links TNF receptor superfamily members to multiple signaling pathways, including NF-κB and JNK activation 1. As an E3 ubiquitin ligase, TRAF5 mediates protein degradation and signal transduction through its RING domain 1. Mechanistically, TRAF5 associates with receptor cytoplasmic domains and kinases to transduce inflammatory and survival signals 1. TRAF5 plays critical roles in immune regulation and disease pathology. Loss of TRAF5 expression is associated with hyperresponsive B cell activation in systemic lupus erythematosus (SLE), where TRAF5-deficient B cells exhibit enhanced TLR7 signaling and autoantibody production 2. In autoimmune diseases, TRAF5 participates in IL-17 receptor signaling complexes; SHP2-mediated displacement of TRAF5 from Act1 enables autonomous IL-17R activation that sustains inflammation despite anti-IL-17 therapy 3. TRAF5 genetic polymorphisms are associated with Behçet's disease and Vogt-Koyanagi-Harada syndrome, with functional variants regulating inflammatory cytokine production 4. TRAF5 hypermethylation reduces gene expression in ankylosing spondylitis, suggesting epigenetic regulation of autoimmune pathogenesis 5. Additionally, TRAF5 mediates AKT ubiquitination and degradation in response to nutrient signals, affecting cancer drug sensitivity 6.

Sources cited
1
TRAF5 mediates NF-κB and MAPK/JNK activation through TNF receptor superfamily signaling and possesses E3 ubiquitin ligase activity via its RING domain
PMID: 17633015
2
TRAF5 is a negative regulator of TLR7; its absence in SLE B cells correlates with hyper-responsiveness and autoreactive plasma cell differentiation
PMID: 30314758
3
TRAF5 forms signaling complexes with Act1 in IL-17R signaling that can be disrupted by SHP2, enabling IL-17-independent inflammation
PMID: 37473759
4
TRAF5 gene polymorphisms are significantly associated with Behçet's disease and VKH syndrome, with functional variants affecting TRAF5 expression and TNF-α/IL-6 production
PMID: 24416204
5
TRAF5 gene hypermethylation in ankylosing spondylitis patients correlates with reduced mRNA expression and disease pathogenesis
PMID: 34021268
6
TRAF5 mediates AKT ubiquitination and degradation in response to amino acid stimulation, regulating cancer drug sensitivity
PMID: 40379466
Disease Associationsⓘ20
multiple myelomaOpen Targets
0.27Weak
mathematical abilityOpen Targets
0.21Weak
hepatocellular carcinomaOpen Targets
0.09Suggestive
posterior cortical atrophyOpen Targets
0.09Suggestive
lung adenocarcinomaOpen Targets
0.07Suggestive
gastric cancerOpen Targets
0.06Suggestive
melanomaOpen Targets
0.06Suggestive
Chronic mucocutaneous candidosisOpen Targets
0.06Suggestive
ulcerative colitisOpen Targets
0.06Suggestive
colitisOpen Targets
0.05Suggestive
isolated agammaglobulinemiaOpen Targets
0.05Suggestive
immune deficiency, familial variableOpen Targets
0.05Suggestive
immunodeficiency 86Open Targets
0.05Suggestive
Crohn's diseaseOpen Targets
0.05Suggestive
Hodgkins lymphomaOpen Targets
0.05Suggestive
classic Hodgkin lymphomaOpen Targets
0.05Suggestive
polyarteritis nodosaOpen Targets
0.05Suggestive
hyper-IgM syndrome type 3Open Targets
0.05Suggestive
MHC class II deficiency 5Open Targets
0.05Suggestive
severe combined immunodeficiency due to CARD11 deficiencyOpen Targets
0.05Suggestive
Pathogenic Variants1
NM_001033910.3(TRAF5):c.1254_1257del (p.Glu419fs)Likely pathogenic
Multiple myeloma
☆☆☆☆2019→ Residue 419
View on ClinVar ↗
Related Genes
XIAPProtein interaction100%TNFRSF8Protein interaction100%CD40Protein interaction100%CHUKProtein interaction100%IKBKBProtein interaction100%LTBRProtein interaction100%
Tissue Expression6 tissues
Bone Marrow
100%
Ovary
88%
Lung
87%
Heart
34%
Brain
26%
Liver
25%
Gene Interaction Network
Click a node to explore
TRAF5XIAPTNFRSF8CD40CHUKIKBKBLTBR
PROTEIN STRUCTURE
Preparing viewer…
PDB7L3L · 2.80 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.94LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.73 [0.57–0.94]
RankingsWhere TRAF5 stands among ~20K protein-coding genes
  • #3,073of 20,598
    Most Researched148 · top quartile
  • #4,777of 5,498
    Most Pathogenic Variants1
  • #8,717of 17,882
    Most Constrained (LOEUF)0.94
Genes detectedTRAF5
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus.
PMID: 30314758
Immunity · 2018
1.00
2
Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
PMID: 34589395
Acta Pharm Sin B · 2021
0.90
3
An autonomous activation of interleukin-17 receptor signaling sustains inflammation and promotes disease progression.
PMID: 37473759
Immunity · 2023
0.80
4
Physiological roles and mechanisms of signaling by TRAF2 and TRAF5.
PMID: 17633015
Adv Exp Med Biol · 2007
0.70
5
High-protein diets alleviate tumour growth and drug resistance by promoting AKT aggregation and turnover.
PMID: 40379466
Gut · 2025
0.60